TAMPA, Fla. — Biomarkers are often used during the management of cancer to guide treatment decisions and predict patient outcomes. However, it is often difficult to identify appropriate biomarkers that that can be consistently reproduced and are easily analyzed with limited patient specimens. In a new study featured on the cover of the May 1 issue of the journal Cancer Research, Moffitt Cancer Center researchers report on their identification of biomarkers based on a type of genetic modification called methylation that predicts the type of tumor immune environment and patient outcomes.
Genes are highly regulated by specific modifications that can either promote or block their expression. One type of epigenetic modification called methylation involves the attachment of a methyl chemical group to particular regions of a gene. Typically, higher levels of methylation at gene promoter regions tend to be associated with lower gene expression levels. Recently, studies have suggested that patterns of genetic methylation could be potential biomarkers. The use of methylation as a biomarker has several advantages over commonly used gene expression biomarkers, including reproducibility and stability that enables it to be easily used in clinical settings, fewer variations among different testing techniques, and the ability to use tissue specimens that are either frozen or fixed in formaldehyde and embedded in paraffin.
Currently, the cytolytic activity score is a biomarker that is well-established and predicts the presence of tumor-infiltrating lymphocytes based on gene expression. Tumor-infiltrating lymphocytes are a type of immune cell that have moved out of the blood and into a tumor. The presence of a high number of tumor-infiltrating lymphocytes in a tumor is typically associated with improved patient prognosis. The cytolytic activity score predicts the presence of tumor-infiltrating lymphocytes, specifically cytotoxic T cells, by measuring gene expression patterns.
In their study, the Moffitt researchers wanted to identify a better biomarker than those commonly used, such as the cytolytic activity score (for identifying hot/cold tumors). They proposed the concept of tumor-based expression quantitative trait methylation that correlates gene methylation patterns with gene expression to identify potential biomarkers. The researchers focused on melanoma as a disease model and assessed whether they could identify a particular methylation signature that could predict what a tumor’s immune environment looks like and patient outcomes.
The researcher team discovered that methylation sequences in melanoma samples could serve as a surrogate biomarker for the cytolytic activity score and predict the type of immune environment in a tumor. By performing a more targeted analysis, they determined that the methylation of a single gene called TCF7 could predict whether T cells in a tumor had anti-tumor properties, and they found that the TCF7 signature combined with the cytolytic activity score predicted patient outcomes. Specifically, melanoma patients with a low TCF7 signature and a high cytolytic activity score had longer survival than other signature combinations. The researchers confirmed the association between low TCF7/high cytolytic activity scores in other tumor types, including kidney carcinoma, esophageal carcinoma, glioma, sarcoma and lung cancer. Additionally, the researchers determined that the TCF7 signature could predict patient outcomes independent of other variables.
“While additional studies need to be performed, these analyses suggest that determining immunoepignomic status through tumor-based expression quantitative trait methylation screening could allow for an accurate prediction of patient outcomes. The discovery unlocks potential new targets for personalized treatment decisions. It is similar to a fingerprint or iris scan, as featured in the cover art for the journal,” said Xuefeng Wang, Ph.D., associate member of the Department of Biostatistics and Bioinformatics and a group lead for computational immunology at Moffitt.
This study was supported by the National Cancer Institute (R01DE030493, R01CA124515, R01CA178687, R01CA211913, P50CA168536, P30-CA076292) and the American Cancer Society (14189-19).
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 52 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,500 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.